Ischemic Cardiomyopathy Market By Diagnosis 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Ischemic Cardiomyopathy Market
Ischemic Cardiomyopathy Market: By Diagnosis (Blood Tests, Imaging Tests, Others), By Medication (Beta-Blockers, ACE inhibitors, others), By Surgical Treatment (Implanting Devices, Angioplasty, Others) & By Region-Forecast (2016-2021)
Report Code : HCR 0333
Updated Date: 28 January, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
Ischemic cardiomyopathy is the disease condition which leads to either heart attack or coronary disease leading to narrowing of the arteries, owing to the main heart muscle getting enlarged and dilated due to weakening of heart muscles. The clinical symptoms of ischemic cardiomyopathy includes shortness of breath, weight gain, heart palpitations, swelling in legs, dizziness, extreme fatigue, chest pain and pressure, insomnia and cough or congestion in lungs. Globally, rising incidence heart attack or coronary disease leading to narrowing of the arteries, increasing research and development activities, rise in the awareness among people regarding diagnosis and treatment of Ischemic cardiomyopathy, and increasing government initiative across the globe, are the prime growth drivers of global ischemic cardiomyopathy market. In addition, rising focus on developing the drugs for treatment of ischemic cardiomyopathy, increase in adoption of ischemic cardiomyopathy treatment in emerging economies such as China, India and others, will create new opportunities for global ischemic cardiomyopathy market. However, higher cost of the research and development, risk of side effects, complex government approval process, and stringent government regulations are the key restraints for global ischemic cardiomyopathy market.

 Ischemic Cardiomyopathy Market

Geographically North America dominated global ischemic cardiomyopathy market, because of high medical reimbursement facilities, and technological advancement. Asia Pacific is projected to have fastest growth, owing to rapidly increasing population, rise in consumer awareness, favourable government policies, and modernization of healthcare infrastructure in developing nations such as China, and India in this region. Among all the treatment, beta-blockers has the highest market share in global ischemic cardiomyopathy market.

This report identifies the global ischemic cardiomyopathy market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to global ischemic cardiomyopathy market.

This report segments global ischemic cardiomyopathy market on the basis of diagnosis, medication, surgical treatment, and regional market as follows:
  • Ischemic Cardiomyopathy Market, By Diagnosis: Blood Tests, Imaging Tests, Electrocardiogram (ECG), Echocardiogram, Stress Test, Coronary Angiography, and Myocardial Biopsy
  • Ischemic Cardiomyopathy Market, By Medication: Beta-Blockers, ACE inhibitors, Aldosterone Inhibitors, Diuretics, and Vasodilators
  • The report has focused study on ischemic cardiomyopathy market by basis of surgical treatment such as: Implanting Devices, Angioplasty, Stents, Atherectomy, and Radiation Therapy
  • This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the ischemic cardiomyopathy market. Some of the major companies’ profiles in detail are as follows:
  • Amgen, Inc.
  • Bioheart, Inc.
  • Cytokinetics, Inc
  • LG Life Sciences, Ltd.
1. Ischemic Cardiomyopathy Market – Market Overview
2. Executive Summary
3. Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
   3.3. Product Benchmarking
   3.4. End User Profiling
   3.5. Top 5 Financials Analysis
4. Ischemic Cardiomyopathy Market– Market Forces
   4.1. Drivers
      4.1.1. Rising incidence heart attack or coronary disease leading to narrowing of the arteries
      4.1.2. Increasing research and development activities
   4.2. Restraints
      4.2.1. Risk of side effects
   4.3. Opportunities
      4.3.1. Emerging economies
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Ischemic Cardiomyopathy Market– Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Ischemic Cardiomyopathy Market, By Diagnosis
   6.1. Blood Tests
   6.2. Imaging Tests
   6.3. Electrocardiogram (ECG)
   6.4. Echocardiogram
   6.5. Stress Test
   6.6. Coronary Angiography
   6.7. Myocardial Biopsy
7. Ischemic Cardiomyopathy Market, By Medication
   7.1. Beta-Blockers
   7.2. ACE inhibitors
   7.3. Aldosterone Inhibitors
   7.4. Diuretics
   7.5. Vasodilators
8. Ischemic Cardiomyopathy Market, By Surgical Treatment
   8.1. Implanting Devices
   8.2. Angioplasty
   8.3. Stents
   8.4. Atherectomy
   8.5. Radiation Therapy
9. Ischemic Cardiomyopathy Market, By Geography
   9.1. Europe
      9.1.1. Germany
      9.1.2. France
      9.1.3. Italy
      9.1.4. Spain
      9.1.5. Russia
      9.1.6. U.K.
      9.1.7. Rest of Europe
   9.2. Asia Pacific
      9.2.1. China
      9.2.2. India
      9.2.3. Japan
      9.2.4. South Korea
      9.2.5. Rest of Asia-Pacific
   9.3. North America
      9.3.1. U.S.
      9.3.2. Canada
      9.3.3. Mexico
   9.4. Rest of the World (RoW)
      9.4.1. Brazil
      9.4.2. Rest of RoW
10. Ischemic Cardiomyopathy – Market Entropy
   10.1. Expansion
   10.2. Technological Developments
   10.3. Merger & Acquisitions, and Joint Ventures
   10.4. Supply- Contract
11. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
   11.1. Amgen, Inc.
   11.2. Bioheart, Inc.
   11.3. Cytokinetics, Inc
   11.4. LG Life Sciences, Ltd.
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
12. Appendix

   12.1. Abbreviations
   12.2. Sources
   12.3. Research Methodology
   12.4. Bibliography
   12.5. Compilation of Expert Insights
   12.6. Disclaimer
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports